Annotation Detail
Information
- Associated Genes
- ERBB2
- Associated Variants
-
ERBB2 MUTATION
ERBB2 MUTATION - Associated Disease
- bladder carcinoma
- Source Database
- CIViC Evidence
- Description
- In patients with muscle-invasive bladder chancer, a cohort of complete responders to platinum chemotherapy (n=38) and non-responders to platinum chemotherapy (n=33) were evaluated for 178 cancer-associated genes. Of the complete responders, 24% had an ERBB2 missense mutations and no non-responders had ERBB2 mutations (p=0.003).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1694
- Gene URL
- https://civic.genome.wustl.edu/links/genes/20
- Variant URL
- https://civic.genome.wustl.edu/links/variants/666
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Bladder Carcinoma
- Evidence Direction
- Supports
- Drug
- Platinum Compound
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25636205
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Platinum Compound | Sensitivity | true |